Combination chemotherapy and adriamycin in patients with advanced breast cancer.A Southwest Oncology Group study
Year: 1976
Type: article
Study design: Clinical Trial
Abstract: In January, 1972, the Southwest Oncology Group initiated two randomized studies for patients with advanced breast cancer. The study for patients with prior chemotherapy showed a 33% response rate with adriamycin. The study for patients without previous chemotherapy consisted of three treatment regimens; a weekly repeated combination of cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone; these same five drugs given in courses of 5 days repeated every 4 weeks; and adriamycin as a single agent every 3 weeks. For the 283 evaluable patients, the response rates were: weekly combination 63/106 (59%); intermittent combination 39/98 (40%); and adriamycin 31/79 (39%). The median duration of response was 8 months for weekly combination, 10 months for intermittent therapy and only 4 months for adriamycin. Leukopenia was the dose-limiting toxicity with all three regimens. The weekly combination is the most effective therapy for patients with advanced disease. Extensive trails of combinations that include adriamycin are underway.
Source: Cancer
Institutions: University of Kansas Medical Center, SWOG Cancer Research Network, European Organisation for Research and Treatment of Cancer, Wayne State University, Swedish Medical Center, The University of Texas Medical Branch at Galveston, Baylor Scott & White Medical Center - Temple, University of Mississippi, Brooke Army Medical Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W2010590441